I noticed the same thing, just what is the catalyst for that? This stock has sometimes gone up & down on no news, we have learnt to be very patient here & conservative, Janssen now have the data from Ph2 ‘on treatment’ with Invokana, so that’s the important one for CDx & monitoring renal function while on treatment.
I really don’t want to disappoint myself thinking this if I’m wrong, but things could finally be happening with Janssen in the near future with CDx.
If you remember back to 2018, Janssen announced a collaboration with the NKF & then we never really heard any more about it (this was when Invokana was approved for CKD/CVD in the USA).
IDK, just tossing some ideas around, we are all only guessing.
PIQ Price at posting:
65.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)